Company Overview
| Stock Name | 金斯瑞生物科技股份有限公司 |
|---|---|
| Stock Code | 01548 |
| Company Full Name | 金斯瑞生物科技股份有限公司 |
| Industry | 醫療保健 |
| Principal Activities | 主要從事提供生命科學研究服務及臨床前藥物研發服務，以及制造及銷售生命科學研究產品及工業合成生物產品。 |
| Listing Date | 2015-12-30 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國江蘇省南京市江寧科學園雍熙路28號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.genscript.com |
| Share Registrar | |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 1.31 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 5.2% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 52,400,000 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 1.32 |
|---|---|
| First Day Open | HK$ 1.44 |
| First Day Change | 0.76% |
| First Day Volume | 45156000.0 |
| First Day Turnover | 63397600.0 |
Use of Proceeds
| Use of Proceeds | 1、約30%或142.6百萬港元，將用于擴充現有生命科學研究與應用服務及產品組合； 2、約30%或142.6百萬港元，將用于擴充產能； 3、約3%或14.3百萬港元，將用于加強信息科技實力； 4、約12%或57.1百萬港元，將用于鞏固銷售及營銷團隊； 5、約15%或71.3百萬港元，將用于可能收購公司的權益或業務，此舉可補充現有業務、將我們的擴充策略與該等收購相融合，及增加收益及溢利； 6、約10%或47.5百萬港元，將用于補充周轉資金及用于一般公司用途。 |
|---|
Underwriting Syndicate
Sole Sponsor (1)
海通国际资本有限公司 CE ADQ859
Overall Coordinators (2)
海通国际证券有限公司 CE AAF806
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
Joint Bookrunners (2)
海通国际证券有限公司 CE AAF806
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
Joint Lead Managers (4)
海通国际证券有限公司 CE AAF806
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
KGI CAPITAL ASIA LIMITED CE ADT039
RHB SECURITIES HONG KONG LIMITED CE ADU220
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 合贸有限公司 | 108,730,000 HKD | — | 5.19% | — | 6 months | 2016-06-30 |
Directors & Management
| Chairman | 孟建革 |
|---|---|
| Company Secretary | 林慧怡 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 章方良及關連人士(40.17%);高瓴資本管理有限公司(7.80%) |
|---|
